Are you helping a loved one get the best help and treatment for a lung cancer diagnosis? Or, maybe you are facing that diagnosis yourself.

Are you looking to find a clinical trial? Do you need help paying for your treatment medications? Do you need to know what the latest research says about treatments for a specific biomarker, like ALK or EGFR? The resources presented here can help you.

Resources & Organizations

This section is where you’ll find links to everything from clinical trials to prescription assistance and much more.

Livestrong

Cancer.net

Lilly Cares Foundation Patient Assistance Program

Boehringer Ingelheim Cares Foundation Patient Assistance Program

Vanderbilt-Ingram Cancer Center: My Cancer Genome

Mesothelioma Applied Research Foundation

NIH ClincalTrials.gov

CancerCare

Ready. Raise. Rise.

Web MD Lung Cancer Overview

National Cancer Institute (NCI)

John Wayne Cancer Foundation (JWCF)

National Coalition For Cancer Survivorship

Your Cancer Game Plan

The Lung Cancer Project

Senior Health

SCBN Prescription Advocacy

Smart Patients Lung Cancer Community

Pfizer Rx Pathways

NCI Clinical Trials Search

CenterWatch

AZ&Me Prescription Savings Program

Antidote Match

Astellas Access Program

Cancer Financial Assistance Coalition

RadiologyInfo.org

Beat The Odds.Org

Stand Up To Lung Cancer

Novartis Patient Assistance Foundation, Inc. (PAF)

International Association For The Study Of Lung Cancer

Planning Your Doctor Visit

Don’t Guess. Test

Medicare.gov: Forms, Help & Resources

Genentech Access Solutions

Lung Cancer Atlas

Lung Cancer Circle Of Hope

Healthwell

Navigating Cancer

With Every Breath: A Lung Cancer Guidebook

Cancer Legal Care

United We Test

LiveLung.org

Pfizer Oncology Together

Personalized Therapies for Lung Cancer brochure cover

Personalized Medicine for Your Lung Cancer Brochures

Partnership For Prescription Assistance

Brittany’s Battle

AACR Survivor & Patient Advocacy Program

Celgene Patient Support

Latest Research

This section presents all of the latest lung cancer research articles presented on the LCFA website. Just click on the tags that interest you.

Five Year Lung Cancer Survival Update

Liquid Biopsy Simpler Sampling

Address Disparities in Lung Cancer Screening

Future of Liquid Biopsy

Bone Marrow Damage Reduced for ES-SCLC Patients

Lower Risk of Brain Mets

With up to 1 year of treatment with imfinzi, an estimated 43% of patients are still alive at 5 years.

Imfinzi increases five year survival to 43%

Role of Postoperative Radiotherapy in NSCLC

Diverse Workforce in Oncology

Cemiplimab-rwlc for NSCLC With High PD-L1

Immunotherapy + Chemo Boosts Response in Resectable NSCLC

New NSCLC Targeted Therapy Guidelines

Effectiveness of immuno-oncology in Medicare population.

Immuno-oncology Effectiveness in Medicare Population

can immunotherapy help early-stage lung cancer patients survive longer?

Immunotherapy For Early-Stage Lung Cancer

Amivantamab Approved for EGFR Exon 20–Positive NSCLC

Sotorasib approved as first treatment for KRAS-G12C positive NSCLC

Sotorasib Approved for KRAS G12C NSCLC

New Treatment Approaches for Small-Cell Lung Cancer

Immune-boosting drug may help before lung cancer surgery

Treating NSCLC With Gene Mutations – Discussion with Dr. Gregory Masters

METex14 Patients See Improved Outcomes Following Savolitinib Treatment

Chromosomal Abnormality and Immunotherapy Response

Why Are ‘Never-Smokers’ Getting Lung Cancer?

Small-Cell Lung Cancer Guidelines

Lung Cancer Rates in the United States

Cancer Patients and the COVID Vaccine

Dr. Alice Berger receives NIH Merit Award

Expand Targeted Therapy for Lung Cancer

Lung Cancer Screening

Telehealth: Bridging the Digital Divide Is Still a Work In Progress

Lung Cancer Care Disparities: Are They Truly Inclusive?

Sotorasib Shows Benefits for KRAS G12C Mutation

Lorlatinib Approved for ALK-Positive NSCLC

Using Both, Immunotherapy and Chemotherapy Doubles Lung Cancer Survival

KRAS Mutation sees Promise for New Therapies

sclc patients show improved outcomes with combination therapy

Patients With Pretreated SCLC Have Improved Outcomes

IASLC Discusses Lung Cancer Care and Research Disparities

Tepotinib Approved for MET+ NSCLC

Breast cancer tops lung cancer as most diagnosed cancer

Why are lung cancer deaths in non-smokers on the rise?

Merck Pulls Keytruda for SCLC

Antibody Hinders EGFR Lung Cancers

Study defines SCLC subtypes

How Biomarkers Impact Treatment Decisions

Genetics influence SCLC risk

Exploring Saliva in Early Lung Cancer Detection

Racial Disparities in Lung Cancer

60.3% of people in study think lung cancer patients are at least partially to blame for their illness

Lung Cancer Stigma: 10 Year Study

Fully half of female lung cancer patients never smoked

‘But I never smoked’: Never smokers and lung cancer

Lung Cancer patients: Make your voices heard about COVID vaccine access!

COVID-19 and Lung Cancer:

Liquid biopsy approved to test multiple genes

First Liquid Biopsy Approved for Multiple Genes

Lung Cancer Screenings Are Down

Tagrisso approved for adjuvant therapy for NSCLC

Tagrisso as Adjuvant Therapy for NSCLC Approved

Trailblazer KRAS treatment filed with FDA

KRAS G12C Treatment gets breakthrough therapy designation from FDA

KRAS G12C Treatment Breakthrough

2020 FDA Approvals of new lung cancer treatments

Treatments for Lung Cancer Newly Available in 2020

Unexpected Finding Reveals New Target for Aggressive Form of Lung Cancer

Aggressive Lung Cancer and new target

Lung Cancer Surgery: Women fare better than men

New KRAS drug could become standard of care for patients with G12C mutation

KRAS G12C mutation drug shows ‘positive’ Phase II results

Targeted therapy effective for RET

Have lung cancer patients experienced changes in treatment due to COVID-19?

Treatment Changes Due to COVID-19

Combination EGFR Therapy Boosts Survival in Early Lung Cancer

KRAS drug tackles 32% of Lung Cancers

RET Fusion-Positive NSCLC treatment gets FDA approval

RET Fusion-Positive NSCLC Treatment Gets Approval

Pan-tumor liquid biopsy gets FDA approval

Pan-Tumor Liquid Biopsy Gets Approval

MET-targeting lung cancer drug gets quick refiew

MET-targeting lung cancer drug gets quick review

RET inhibitor for lung cancer

racial disparity in lung cancer incidence

Racial disparities in lung cancer

Patient having chemotherapy treatment for SCLC

FDA Accepts NDA for Trilaciclib for SCLC

Lung Cancer Mortality Rates Drop Sharply

Improved Progression-Free Survival

Treatments Expand for EGFR-positive NSCLC

FDA AApproves small cell lung cancer treatment

FDA Approves Small Cell Lung Cancer (SCLC) Treatment

COVID19 severity and lung cancer

Tagrisso cuts lung cancer recurrence by 83%

Nivolumab plus Ipilimumab and Chemotherapy Approved for First-Line Treatment

Combination Therapy Aproved for First-Line Treatment

FDA approves treatment for NSCLC with MET Exon 14 skipping

NSCLC with MET exon 14 skipping Treatment Approved

End the Debate on Biomarker Testing for NSCLC

New guidelines for lung cancer screenings

African Americans and Lung Cancer Screening

lung cancer treatment progress over the past decade

Lung Cancer Treatment Progress Over the Last Decade

High BMI Linked to Better Immunotherapy Outcomes for NSCLC

Immunotherapy and BMI

Testing lung cancer patients for COVID-19

Testing Patients with Lung Cancer for COVID-19

Conducting Clinical Trials During Coronavirus Pandemic

Does Delaying ALK+ Treatment Impact Survival?

Durvalumab Approved for SCLC

African American Lung Cancer Patients less likely to receive lung cancer imaging

Coronavirus and Cancer: 1-2 Punch

When Cancer And Coronavirus Collide

Biomarker Testing and CT Screening Vital for Lung Cancer

Faulty Immune System May Lead to Lung Cancer

World Health Organization classifies air pollution as a carcinogen

Is Lung Cancer Related to Air Pollution?

Acquired Drug Resistance Strategy

Death Rate Drop: Lung Cancer Research Key

Small Cell Lung Cancer (SCLC)

Treatment Refusal for Small Cell Lung Cancer

How Are We Failing Lung Cancer Patients so Miserably?

Liquid Biopsies and NSCLC

Lung cancer screening guidelines do not detect disease among first responders.

Inadequate Lung Cancer Screening Guidelines for First Responders

Liquid Biopsies and Molecular Testing in Lung Cancer

Nasal-Swab Lung Cancer Test

Tecentriq: IMpower-ing results

MET Treatment Gets Breakthrough Designation

RET Drug Shrinks Tumors in Trial

Small Cell Lung Cancer: Immunotherapy Infinzi prolings survival

I/O Imfinzi prolongs survival

TMB and Lung Cancer Treatment

KRAS Treatment Shows Promise

FDA Approves entrectinib for ROS1 and NTRK

Entrectinib approved for ROS1 and NTRK

Liquid Biopsy: Are We Ready for a ‘Blood-First’ Approach?

Long-Term Survival for EGFR+

Blood Test Could Identify Potential Lung Cancer Markers

what could a clinical trial navigator do for you?

Clinical Trial Navigators

FDA approves Keytruda for SCLC

The Relationship Between Air Pollution and Lung Cancer in Nonsmokers

What good is it to cure cancer if we routinely fail to deliver that cure?

What good is it to be able to cure cancer if we routinely fail to deliver that cure?

Artificial intelligence and cancer

Know Your Genes: Testing for Genomic Mutations in Lung Cancer

Lung Cancer Stigma: Not Just the Patient’s Problem

Brushing airway tissue to predict the development of lung cancer

Could invigorating the immune system prevent lung cancer?

Precision of Liquid Biopsy and Osimertinib Resistance

Current Open Clinical Trials

FDA approves new treatment for extensive-stage small cell lung cancer

El Paso County Public Health advises people to test homes for radon

Antibiotics or anti-inflammatory drugs may help combat lung cancer

New treatment options for ROS1, BRAF, and NTRK biomarkers in lung cancer

New Treatment Options for ROS1, BRAF, and NTRK Alterations in NSCLC

New study predicts which lesions will become cancerous

Molecular profiling could catch lung cancer early and lead to new treatments

New Protein found linked to lug cancer treatment resistance

New Protein Found Linked to Lung Cancer Treatment Resistance

How bias in the medical community hurts lung cancer patients

What happens when the doctor blames you for your own cancer?

Patients now living a median 6.8 years after stage IV ALK+ lung cancer diagnosis

Lung Cancer Deaths are 28 Percent Lower in California

Appropriate biomarkers needed in patient selection for immunotherapy

First-Line Immunotherapy Combo Fails to Improve Survival in Lung Cancer Trial

New FDA Approval: Combination therapy for lung cancer

FDA Approves Atezolizumab Combination

Policy changes needed for access to lung cancer research.

Policy changes needed for access to lung cancer treatments

New DNA sequencing test credited with saving his life

Personalized Medicine for NTRK Fusion-Positive Solid Tumors

Women with lung cancer live longer than men

After Decades, New Standard of Care in Small Cell Lung Cancer

Can body fluids help spot lung cancer?

Air Pollution Increases Lung Cancer Risk in Nonsmokers

Lung cancer patient and activist, Janet Freeman-Daily with Dr. Russ Camidge, University of Colorado

The Power of Patients

Safe, Effective Treatment for Early-Stage Lung Cancer

Anti-cancer treatment designed to lower risk of cancer’s return

Combination Therapy Study Reduces Risk of Death by Half

Broad-Based Testing: Will it Improve Survival?

FDA Approves Opdivo for Small Cell Lung Cancer

Researchers Use Big Data to Predict Immunotherapy Responses

Blood test found that can accurately identify lung cancer patients who could benefit from immunotherapy.

Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer

Lung cancer mortality rates among women expected to increase.

Lung cancer mortality rates among women projected to increase

Could a Simple Blood Test Detect Early-Stage Lung Cancer?

Biomarker blood test better able to identify smokers who later develop lung cancer

Blood test improves lung cancer risk assessment for smokers

Can combination therapy increase lung cancer survival

Combination Therapy New Standard of Care for Squamous NSCLC

UCLA Clinical Trials - May and June, 2018

New Combination Therapy Clinical Trial for UCLA

New non-invasive method to detect lung cancer now in clinical trial

New Noninvasive Method for Lung Cancer Screening

Why non-smokers are getting lung cancer

US Vets 75% more likely to develop lung cancer

Lung Cancer Research gains $6,000,000 for 2019

Combination Therapy for Small Cell Lung Cancer

Study: Keytruda better than chemo against advanced lung cancer

Risk of LC drops within 5 years of quitting smoking

New research finds lung cancer risk drops substantially within five years of quitting smoking

Lung cancer rates in young women raise concerns

Low Lung Cancer Screening Rate

Immunotherapy Combination Increases Lung Cancer Survival

Testing for all lung cancer mutations at once found cost effective

Attention: Extensive-stage small cell lung cancer patients

New liquid biopsy-based cancer model reveals data on Small Cell Lung Cancer

New liquid biopsy-based cancer model reveals data on deadly lung cancer

What Is EGFR and How Does It Relate to Lung Cancer?

Immuno therapy scores big win against lung cancer in study

NSCLC with EGFR gets new first-line treatment

NSCLC with EGFR mutations gets new first-line treatment approved by FDA

ALK-positive non-small cell lung cancer gets boost from Lorlatinib

Scientists identify 170 potential lung cancer drug targets

LCFA Grant recipient gets write-up in New England Journal of Medicine

Dr. Kellie Smith: Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

Lung cancer patients live longer with immuno-therapy

Lung Cancer Patients Live Longer With Immune Therapy

Outpatient Immunotherapy for Lung Cancer

Tecentriq plus chemo cut risk of death in type of lung cancer

UCLA Opens New Trial for Stage IV NSCLC Patients

FDA Approves 4-Week Nivolumab Dosing Schedule

Inhalation to be Used in New Trial for Second-Line NSCLC Patients

Merck’s Ace Keytruda Impresses Again, Stuns in Phase III Lung Cancer Trial

FDA Expands Afatinib’s Approval for Lung Cancer

Many Elderly Lung Cancer Patients Receive No Treatment

Seeking Consensus Amid Abundant New Lung Cancer Data

Targeted Therapies Convey Survival Benefit in Patients With Lung Cancer

The Biggest Cancer News Of 2017? ‘CAR-T Cells, Hands Down’

Will Immunotherapy And Radiation Be Combined In Lung Cancer Treatment?

It’s Crucial That Patients Identify The Mutations Driving Their Lung Cancers

UCLA Lung Cancer Screening and Early Detection

James Cancer Center Ohio State Univeristy

Active Therapeutic Thoracic Trials – December 2017

FDA grants approval for in vitro diagnostic

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Liquid Biopsies: A Lung Cancer Game-Changer?

Ohio State University Comprehensive Cancer Center

Active Therapeutic Thoracic Trials – November 2017

Tumor Mutation Burden Shows Promise as a Response Biomarker in Small Cell Lung Cancer

Dr. Steve Dubinett, Dr. Julie Brahmer, Kim Norris, President, LCFA

LCFA trio contribute to ‘cancer interception’ project

Alecensa Approved as First-Line Treatment

Immunotherapy for Lung Cancers: First-Line and Beyond

iSABR Trial for Early-Stage, Unresectable NSCLC Now Open

Phase 2 Study of Next-Generation Investigational ALK-Inhibitor Lorlatinib

Clinical Trial News from UCLA

We’re more likely to get cancer than to get married.

Opdivo Improves Long-Term Survival in Advanced Lung Cancer

Dr. David Carbone, The Ohio State University

Lung Cancer: Is Your Doctor Screening You for the Best Treatment?

Are results from immunotherapy in lung cancer durable?

Merck’s immunotherapy, chemo mix shows extended lung cancer gains

New treatment news for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Blood tumor markers may warn when lung cancer patients are progressing

Keytruda Shows Promise in Small Cell Lung Cancer

Changing Treatment Paradigm for ALK-Positive Lung Cancer

Blood test can predict early lung cancer prognosis

Blocking Post-MI Inflammation Tied to Fewer Lung Cancer Deaths

Blood Test Finds Cancer Before Symptoms Start

Newly Diagnosed with Lung Cancer? Get a Second Opinion

Too Many Drugs in Too Many Trials and Not Enough Patients?

Lung cancer diagnosis increases suicide risk by 420%

New Trial for NSCLC Patients with no Previous Immunotherapy Opens

Alecensa Gets Priority Review For Initial Treatment Of People With ALK-Positive Lung Cancer

Lung cancer patient reflects on information

Changes to Improve Usability of ClinicalTrials.gov

New CDC Report Shows Deaths from Cancer Higher in Rural America

Full FDA Approval Granted for Anti-Cancer Drug Targeting EGFR Protein Found in Lung Cancer and Mesothelioma

FDA Approves Tafinlar, Mekinist Combo to Treat BRAF V600E Non-Small Cell Lung Cancer

With Patients Reporting Symptoms Using Web Tool, Survival Improves

Combined immune checkpoint blockade shows promise for small cell lung cancer

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Lab on a Chip Outlines New Liquid Biopsy Technology

Improved Survival Using Imfinzi In Sequential Treatment in NSCLC

FDA Approves Keytruda Combo for Lung Cancer

Brigatinib

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

DNA-based test can spot cancer recurrence a year before conventional scans

Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Can we make the affordable healthcare act better?

AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

Drug Offers Some Hope for a Deadly Lung Cancer

‘Bad luck’ mutations increase cancer risk more than behavior, study says

Immunotherapy Trial for EGFR Mutation Positive Patients to Expand Enrollment

Advice From Patients On A Study’s Design Makes For Better Science

Update: CRISPR

Trial for Patients Doing Well on Nivolumab Expands to UCLA

Stand Up To Cancer Ushers In New Approach to Research

Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

Multimillion Dollar Grant Awarded from the National Cancer Institute for Translational Research at UCLA and in TRIO-US

Personalized Medicine Impacting Study Conduct

Immunotherapy Agent Improved Quality of Life in Lung Cancer Study

No Personalized Treatments for 20% of Newly Diagnosed

Living Under a Cloud: Examining Air Pollution’s Effects on Lung Cancer

Brigatinib Demonstrated 15.6 Month Systemic Median Progression-Free Survival

AstraZeneca pill slashes lung cancer progression in study

New application of existing drug offers personalized therapy for lung cancer

Safety and Efficacy of ABRAXANE® for Challenging Patient Populations

KEYTRUDA Data in Small Cell Lung Cancer and Mesothelioma

Microsoft Shows Searches Can Boost Early Detection of Lung Cancer

Liquid Biopsy — “Powerful Tool” In Precision Lung Cancer Therapy, Study Shows

Alectinib and ALK-Positive Non-Small Cell Lung Cancer

Blue Ribbon Panel Presentation to National Cancer Advisory Board for Cancer Moonshot

Videos

In this section, you’ll find interviews with the key opinion leaders in lung cancer research on the topics pertinent to lung cancer patients, survivors and caregivers.

Advances in Lung Cancer Research

Advocacy – Lung Cancer Foundation of America (LCFA)

Biopsies and Tissue Sample Size

Caregivers

Clinical Trials

Deadly Dancer

Early Detection

Everyday Stories and Realities of Lung Cancer

Findings from the National Lung Screening Trial

Genetic Mutations in Lung Cancer

Hope

Dr. Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center

How To Get Your Tumor Tested

I’ve Got Lung Cancer

LCFA Grants: How They Help

Thumbnail of Dr. Heather Wakalee and the stigma of lung cancer

Lung Cancer Stigma

Need For Funding

Our Mission

Pace of Research

Research

Second Opinions

Thumbnail of Dr. David Carbone discussing lung cancer treatments

Selecting A Doctor

Targeted Therapies

Using Early Detection to Improve Patient Outcomes

What Does Dr. Donington Research?

Why Is Targeted Therapy Important

Learn more

Life should take your breath away, not lung cancer.

Knowledge is power: Sign up for regular emails from the Lung Cancer Foundation of America to get more resources on lung cancer risks, symptoms and warning signs.

What Can We Help You Find?

Resources & Organizations

Livestrong

Cancer.net

Lilly Cares Foundation Patient Assistance Program

Boehringer Ingelheim Cares Foundation Patient Assistance Program

Vanderbilt-Ingram Cancer Center: My Cancer Genome

Mesothelioma Applied Research Foundation

NIH ClincalTrials.gov

CancerCare

Ready. Raise. Rise.

Web MD Lung Cancer Overview

National Cancer Institute (NCI)

John Wayne Cancer Foundation (JWCF)

National Coalition For Cancer Survivorship

Your Cancer Game Plan

The Lung Cancer Project

Senior Health

SCBN Prescription Advocacy

Smart Patients Lung Cancer Community

Pfizer Rx Pathways

NCI Clinical Trials Search

CenterWatch

AZ&Me Prescription Savings Program

Antidote Match

Astellas Access Program

Cancer Financial Assistance Coalition

RadiologyInfo.org

Beat The Odds.Org

Stand Up To Lung Cancer

Novartis Patient Assistance Foundation, Inc. (PAF)

International Association For The Study Of Lung Cancer

Planning Your Doctor Visit

Don’t Guess. Test

Medicare.gov: Forms, Help & Resources

Genentech Access Solutions

Lung Cancer Atlas

Lung Cancer Circle Of Hope

Healthwell

Navigating Cancer

With Every Breath: A Lung Cancer Guidebook

Cancer Legal Care

United We Test

LiveLung.org

Pfizer Oncology Together

Personalized Medicine for Your Lung Cancer Brochures

Partnership For Prescription Assistance

Brittany’s Battle

AACR Survivor & Patient Advocacy Program

Celgene Patient Support

Latest Research

Five Year Lung Cancer Survival Update

Liquid Biopsy Simpler Sampling

Address Disparities in Lung Cancer Screening

Future of Liquid Biopsy

Bone Marrow Damage Reduced for ES-SCLC Patients

Lower Risk of Brain Mets

Imfinzi increases five year survival to 43%

Role of Postoperative Radiotherapy in NSCLC

Diverse Workforce in Oncology

Cemiplimab-rwlc for NSCLC With High PD-L1

Immunotherapy + Chemo Boosts Response in Resectable NSCLC

New NSCLC Targeted Therapy Guidelines

Immuno-oncology Effectiveness in Medicare Population

Immunotherapy For Early-Stage Lung Cancer

Amivantamab Approved for EGFR Exon 20–Positive NSCLC

Sotorasib Approved for KRAS G12C NSCLC

New Treatment Approaches for Small-Cell Lung Cancer

Immune-boosting drug may help before lung cancer surgery

Treating NSCLC With Gene Mutations – Discussion with Dr. Gregory Masters

METex14 Patients See Improved Outcomes Following Savolitinib Treatment

Chromosomal Abnormality and Immunotherapy Response

Why Are ‘Never-Smokers’ Getting Lung Cancer?

Small-Cell Lung Cancer Guidelines

Lung Cancer Rates in the United States

Cancer Patients and the COVID Vaccine

Expand Targeted Therapy for Lung Cancer

Lung Cancer Screening

Telehealth: Bridging the Digital Divide Is Still a Work In Progress

Lung Cancer Care Disparities: Are They Truly Inclusive?